DFD-03 Lotion, 0.1% + Tazorac Cream, 0.1% + DFD-03 Vehicle Lotion 0% + Tazorac Vehicle Cream 0%

Phase 2Completed
2 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acne Vulgaris

Conditions

Acne Vulgaris

Trial Timeline

Aug 21, 2017 → May 18, 2018

About DFD-03 Lotion, 0.1% + Tazorac Cream, 0.1% + DFD-03 Vehicle Lotion 0% + Tazorac Vehicle Cream 0%

DFD-03 Lotion, 0.1% + Tazorac Cream, 0.1% + DFD-03 Vehicle Lotion 0% + Tazorac Vehicle Cream 0% is a phase 2 stage product being developed by Dr. Reddy's Laboratories for Acne Vulgaris. The current trial status is completed. This product is registered under clinical trial identifier NCT03341910. Target conditions include Acne Vulgaris.

What happened to similar drugs?

20 of 20 similar drugs in Acne Vulgaris were approved

Approved (20) Terminated (0) Active (0)
IsotretinoinSun PharmaceuticalApproved
Winlevi (Clascoterone) cream 1%Sun PharmaceuticalApproved
Winlevi (clascoterone) 1% & Duac gelSun PharmaceuticalApproved
Winlevi (clascoterone) 1% creamSun PharmaceuticalApproved
Winlevi (clascoterone) 1% creamSun PharmaceuticalApproved
Winlevi (clascoterone) 1% creamSun PharmaceuticalApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03341910Phase 2Completed

Competing Products

20 competing products in Acne Vulgaris

See all competitors
ProductCompanyStageHype Score
DFD-03Dr. Reddy's LaboratoriesPhase 3
37
Tazarotene Lotion, 0.1% + Tazarotene Cream, 0.1%Dr. Reddy's LaboratoriesPhase 2
32
DFD-03 (0.1% tazarotene) Lotion + DFD-03 (0% tazarotene) Lotion (Placebo)Dr. Reddy's LaboratoriesPhase 3
37
Olumacostat Glasaretil Gel, 5.0%Eli LillyPhase 3
40
HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 PlaceboHoth TherapeuticsPhase 2
32
Trifarotene Cream 0.005% + AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG + AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT + PlaceboSun PharmaceuticalPhase 1
29
Tretinoin Gel Microsphere, 0.1% + RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% + Placebo ControlSun PharmaceuticalPhase 1
29
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% + Acanya® Gel, 1.2%/2.5% + Vehicle of test productSun PharmaceuticalPhase 1
29
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel + Duac® Topical Gel + Placebo Topical GelSun PharmaceuticalPhase 1
29
Adapalene Gel 0.1% + Placebo Control + Differin® Gel (Adapalene 0.1%, Galderma)Sun PharmaceuticalPhase 1
29
Trifarotene Cream 0.005% + Placebo + AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)Sun PharmaceuticalPhase 1
29
Adapalene/BP gel, 0.3%/2.5% + EPIDUO® FORTE + PlaceboSun PharmaceuticalPhase 1
29
ADPS topical product + Placebo ControlSun PharmaceuticalPhase 2
35
IsotretinoinSun PharmaceuticalApproved
43
Winlevi (Clascoterone) cream 1%Sun PharmaceuticalApproved
47
Adapalene Gel 0.3% + Differin® + PlaceboSun PharmaceuticalPhase 1
29
CLPG Topical Gel 1% + Clindamycin + PlaceboSun PharmaceuticalPhase 1
29
Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% + Epiduo® Gel + PlaceboSun PharmaceuticalPhase 1
29
Test. + Aczone Gel 5% + PlaceboSun PharmaceuticalPhase 1
29
Clindamycin and Benzoyl Peroxide Gel 1%5% + BenzaClin® Topical Gel + PlaceboSun PharmaceuticalPhase 1
29